Gentian Violet
FDA-approved product (suppository, vaginal), marketed as Genapax, Gvs.
- Registered studies
- 8
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Gentian Violet. Its therapeutic class is shown instead.
- Anti-infective classification
- Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.
Repurposing investigation
Gentian Violet reaches ≥40% AI-predicted activity against M. tuberculosis, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.
AI-predicted activity
AI prediction · nothing measured- MRSA22.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli21.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae3.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
8registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Gentian Violet with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli
NCT07482553 · start 2026-05-01
Registered record
- Registry ID
- NCT07482553
- Conditions
- Urinary Tract Infections (UTIs); Catheter-Associated Urinary Tract Infections (CAUTIs); Biofilm Formation by Uropathogenic Escherichia Coli (UPEC)
- Interventions
- chitosan nanoparticles
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Not yet recruiting
- Start
- 2026-05-01
- Completion
- 2027-06
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrinary Tract Infections (UTIs); Catheter-Associated Urinary Tract Infections (CAUTIs); Biofilm Formation by Uropathogenic Escherichia Coli (UPEC)Interventionchitosan nanoparticlesPhaseNot recordedRegistry statusNot yet recruitingGentian Violet Treatment for Hidradenitis Suppurativa
NCT04388163 · start 2025-08
Registered record
- Registry ID
- NCT04388163
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Gentian Violet
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2025-08
- Completion
- 2026-12
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHidradenitis SuppurativaInterventionGentian VioletPhasePhase 2Registry statusWithdrawnHidradenitis Suppurativa Wound Care
NCT04354012 · start 2021-02-04
Registered record
- Registry ID
- NCT04354012
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- methylene blue, gentian violet, and ovine forestomach wound dressings
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2021-02-04
- Completion
- 2024-08-28
- Enrolment
- 5
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHidradenitis Suppurativa (HS)Interventionmethylene blue, gentian violet, and ovine forestomach wound dressingsPhasePhase 2Registry statusCompletedAntibacterial and Anti-biofilm Activity of Frankincense Extract Against Porphyromonas Gingivalis
NCT04705714 · start 2021-01-15
Registered record
- Registry ID
- NCT04705714
- Conditions
- Periodontal Diseases
- Interventions
- Frankincense Extract
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2021-01-15
- Completion
- 2021-03-01
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPeriodontal DiseasesInterventionFrankincense ExtractPhasePhase 1Registry statusCompletedAccuracy for Predicting Deep Submucosal Invasion
NCT03748667 · start 2018-12-01
Registered record
- Registry ID
- NCT03748667
- Conditions
- Colorectal Cancer; Colorectal Polyp
- Interventions
- White light endoscopy (WLE); NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2018-12-01
- Completion
- 2022-10-30
- Enrolment
- 426
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal Cancer; Colorectal PolypInterventionWhite light endoscopy (WLE); NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)PhaseNot recordedRegistry statusCompletedInvestigation of Bacterial Adhesion and Bactericide Effect ex Vivo on Different Implant Restoration Materials
NCT04657757 · start 2018-03-14
Registered record
- Registry ID
- NCT04657757
- Conditions
- Dental Diseases
- Interventions
- Intraoral apparatus
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2018-03-14
- Completion
- 2020-03-31
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDental DiseasesInterventionIntraoral apparatusPhaseNot applicableRegistry statusCompletedGentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis
NCT01427738 · start 2011-06
Registered record
- Registry ID
- NCT01427738
- Conditions
- HIV-1 Infection
- Interventions
- Gentian Violet; Nystatin oral suspension
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-06
- Completion
- 2014-01
- Enrolment
- 221
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-1 InfectionInterventionGentian Violet; Nystatin oral suspensionPhasePhase 3Registry statusCompletedA Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis
NCT00128323 · start 2002-11
Registered record
- Registry ID
- NCT00128323
- Conditions
- Candidiasis, Oral
- Interventions
- Gentian violet 1% solution; Gentian violet 0.00165% solution; Nystatin solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-11
- Completion
- 2005-04
- Enrolment
- 558
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasis, OralInterventionGentian violet 1% solution; Gentian violet 0.00165% solution; Nystatin solutionPhasePhase 3Registry statusCompleted